Oct 29, 2026 earnings call — NovaSeq X placements drive revenue and guidance raise
Illumina raised full-year revenue guidance by $30 million to $4.64 to 4.66 billion.
Revenue $1.2B (est $1.2B) · EPS $1.62 (est $1.36) · Next-quarter revenue outlook $1.2B–$1.2B
Key quotes
"In the quarter, we placed over 80 instruments. This equates to approximately 360 NovaSeq X placements over the last four quarters, more than in our first year of launch."
"We are raising our revenue guidance by $30 million at the midpoint to $4.64 to 4.66 billion."
Analyst Q&A 14
clinical consumables growth and Q4
Q (Tycho Peterson · Jefferies): Analyst asked if there were any stocking orders to note and whether Q4 implies low double-digit clinical growth as a base for next year.
A: Management said they are pleased with clinical performance and expect full-year clinical growth in the mid-teens. Q3 looked like Q2 with 14% to 15% growth, and they expect that to continue; leadership said Q4 is coming along well.
"We see ourself the full year in the mid-teens." — Jacob Thaysen (CEO)
2027 outlook and instrument effects
Q (Vijay Kumar · Evercore): Analyst asked what framework should be used for 2027 given the Q4 jump-off and whether LRP targets remain intact; could instrument placements become a headwind next year?
A: Management said they will provide full 2027 guidance in the Q4 call but framed the outlook: clinical market is healthy and multi-omics and AI create additional opportunities. They noted consumables have grown above 5% each quarter this year and that elevated NovaSeq X placements should be a driver into growth.
"What I will leave you with is that, and how I think about the next year, is that we have over the last quarters in this year, each quarter, we have been growing our consumables above 5%." — Jacob Thaysen (CEO)
NovaSeq X demand sustainability and mix
Q (Doug Schenkel · UBS): Analyst asked whether recent strong X placements reflect pull-forward demand versus sustainability, and how much of demand was capacity expansion for clinical versus transitions/replacements.
A: Management said they do not see pull forward and view placements as normal business activity. They highlighted strong placements over the last four quarters, a healthy clinical market, sequencing-intensive new assays, and customers viewing X as the platform to bet on, supporting continued strong demand.
"I do not think there was any pull forward." — Jacob Thaysen (CEO)
sequencing consumable dynamics and 2027
Q (Puneet Souda · Leerink): Analyst asked if lower cost per gigabase from new instruments is driving elasticity and whether the high single-digit 2027 framework is still intact.
A: Management said the transition from 6K to X included a price step down but generated substantially more and continuing volume, with customers building bigger assays especially in clinical oncology. They added pricing conversations exist for large-volume customers and said they remain on track to deliver 2027 high single-digit growth.
"we still are on the track to deliver on the 2027 of high single digit in that range." — Jacob Thaysen (CEO)
new product contribution and margins
Q (Subbu Nambi · Guggenheim): Analyst asked whether new products could add 1–2 points of growth by 2027 and whether exiting 2026 at 25% operating margin is the right starting point for further margin improvement.
A: Management said their multi-omics portfolio and the SomaLogic acquisition have momentum from a low base and will start to show in 2026 and more in 2027 and beyond. They noted margin improvement of 400 basis points over recent years despite headwinds and said they feel good about further improvement into 2027.
"We have come out over the last 18 months with a very, very significant multi-omics portfolio, and also with the acquisition of SomaLogic, we are very well-positioned in that space." — Jacob Thaysen (CEO)
clinical conversions to X and test impact
Q (Luke Sergott · Barclays): Analyst asked how conversions of many liquid biopsy players to X affect initial concordance studies and when samples flip onto X, given the exit rate implications for clinical sequencing.
A: Management said the pattern is as expected: elevated X placements drive long-term consumables revenue because instruments are used to generate future revenue. They emphasized a very healthy clinical market with many applications coming online and noted USCAN clinical business has grown strongly.
"So obviously, every time you place an X, that is a revenue generator for the years to come." — Jacob Thaysen (CEO)
genome pricing and AI training data
Q (Dan Arias · Stifel): Analyst asked whether very low-cost genomes force revisiting price elasticity to win large AI training projects, or if current pricing is sufficient until new flow cell improvements.
A: Management said AI model work is about much more than whole-genome price and that Illumina can create large, multi-omic, reproducible datasets across genome, transcriptome, methylome and proteome which are critical for AI. They said Illumina is uniquely positioned with broad portfolio and datasets like the Billion Cell Atlas, and they are comfortable addressing elasticity with customers.
"It is about the ability to develop and create large data sets that goes across both the genome, the transcriptome, the methylome, and of course, also the proteome." — Jacob Thaysen (CEO)
clinical growth and customer discounts
Q (Dave Westenberg · Piper Sandler): Analyst asked how fast clinical (70% of consumables) can grow to lift overall growth to high single digits and what discounting is needed to capture large customers' volume.
A: Management said they work closely with customers and see customers building bigger assays tied to therapy selection and MRD, and when customers grow, Illumina grows too. They noted they have a mid-single consumables growth track record and can expand; management added that U.S. clinical growth rate is well above 14% and Illumina benefits globally.
"Within our U.S. business, the growth rate within that clinical is well above the 14% that you're talking about." — Ankur Dhingra (CFO)
upside beyond high single-digit growth
Q (Kyle Mikson · Canaccord Genuity): Analyst asked whether Illumina could exceed high single-digit growth, possibly approach double-digit growth, while expanding margins to the high 20s, and what that would require.
A: Management said upside beyond high single digit is possible but they want to demonstrate high single-digit execution first given past headwinds. They highlighted large market opportunity in clinical, multi-omics when research recovers, and AI datasets as drivers that could enable growth beyond their current target.
"There is definitely upside to a high single digit growth." — Jacob Thaysen (CEO)
BioInsight timing in P&L
Q (Dan Leonard · RBC): Analyst asked when BioInsight will become visible in the P&L — next year or later.
A: Management said BioInsight combined software and data about a year ago and that multi-omics and data were expected to start generating 1%-2% in the latter part of their 2024 strategic period, particularly in 2027. They added that if AI scales, the opportunity could be substantially bigger and that they expect some color to emerge in 2027.
"Yeah, I think our view right now is somewhere in 2027, there should be some sort of color we should be able to begin to add." — Ankur Dhingra (CFO)
extra week impact and China status
Q (Casey Woodring · JPMorgan): Analyst asked how much the extra selling week helps Q4 revenue and whether anything changed with Chinese authorities or customer comfort given the Unreliable Entity List.
A: Management said they are pleased to be back to growth in China, remain committed to serve Chinese customers, and are working to understand recent developments; they are not forecasting any specific budget flush beyond normal Q4. They added the extra week in Q4 was included in guidance, falls in holidays, has minimal revenue impact and modest extra people costs.
"The extra week in Q4 has always been part of our guidance throughout this year." — Ankur Dhingra (CFO)
AI service vs instrument and BCA data types
Q (Dan Brennan · TD Cowen): Analyst asked whether AI opportunity is mainly service (BioInsight) or instrument/flow-cell driven, whether BCA focuses on single-cell/multi-omics versus whole genome, and for any NovaSeq X pricing color.
A: Management said customers want large, reproducible standardized datasets and there is a huge opportunity for Illumina in a service business format while instrument placements will also play a role. They expect a blend of service and instrument demand and highlighted the company's expertise building high-quality perturbation datasets; multi-omic combinations will be important for future datasets.
"There's certainly a huge opportunity for Illumina in what you can call in a service business format." — Jacob Thaysen (CEO)
China growth and future outlook
Q (Dave Westenberg · Piper Sandler): Analyst asked what drove the reported and organic growth numbers in China for the quarter and how to think about China going forward given the Unreliable Entity List.
A: Management said they are committed to finding a path forward in China, maintain good relationships, and focus on supporting customers and driving innovation. They see strong interest in their innovations and believe the opportunity in China is large.
"We see a lot of interest for a lot of our innovations in China, and we believe the opportunity in China is big." — Jacob Thaysen (CEO)
operating leases and reagent rental models
Q (Tycho Peterson · Jefferies): Analyst asked Ankur to elaborate on operating leases and whether reagent rental models might spill over into clinical.
A: Management said operating leases and reagent rental models have been offered for a long time and demand is growing in both research and clinical. They noted largest clinical customers have used less due to capacity expansion, but mid-sized clinical labs in U.S. and Europe are showing pickup; the offering is available globally.
"Both the entire operating leases as well as reagent rental models, we have had them on the offer for a fairly long period of time." — Ankur Dhingra (CFO)